{"filing":{"accession_number":"0001493152-26-035621","cik":"0001595353","ticker":"GLMD","company_name":"Galmed Pharmaceuticals Ltd.","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595353/000149315226035621/form6-k.htm"},"events":[{"id":22381,"run_id":20244,"accession_number":"0001493152-26-035621","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Galmed received notice from Nasdaq on July 30, 2026, that it has failed to maintain the minimum $1 bid price per share requirement and has been granted an additional 180-day compliance period (until January 25, 2027) to cure the deficiency. This is a classic delisting-risk disclosure under Item 3.01 — the company faces potential delisting if it cannot regain compliance within the extended cure period.","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":22304,"accession_number":"0001493152-26-035621","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Galmed received notice from Nasdaq on July 30, 2026, that it has failed to maintain the minimum $1 bid price per share requirement and has been granted an additional 180-day compliance period (until January 25, 2027) to cure the deficiency. This is a classic delisting-risk disclosure under Item 3.01 — the company faces potential delisting if it cannot regain compliance within the extended cure period.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:10:19.578490+00:00","company_name":"Galmed Pharmaceuticals Ltd.","ticker":"GLMD","filing_date":"2026-07-31"}]}